Pathogenesis and management of Kawasaki disease

References

• Amano S, Hazama F, Kubagawa H, Tasaka K, Haebara H, Hamashima Y. General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations. Acta Pathol. Jpn30(5), 681–694 (1980).
   PubMedGoogle Scholar
• Rowley AH, Baker SC, Orenstein JM, Shulman ST. Searching for the cause of Kawasaki disease – cytoplasmic inclusion bodies provide new insight. Nat. Rev. Microbiol.6(5), 394–401 (2008).
   PubMedGoogle Scholar
• Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J. Infect. Dis.184(7), 940–943 (2001).
   PubMed Web of Science ®Google Scholar
• Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J. Immunol.159(12), 5946–5955 (1997).
   PubMedGoogle Scholar
• Rowley AH, Shulman ST, Mask CA et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J. Infect. Dis.182(4), 1183–1191 (2000).
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Rowley A, Schulte DJ et al. Activated myeloid dendritic cells accumulate and co-localize with CD3+ T cells in coronary artery lesions in patients with Kawasaki disease. Exp. Mol. Pathol.83(1), 93–103 (2007).
   PubMedGoogle Scholar
• Hirao J, Hibi S, Andoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int. Arch. Allergy Immunol.112(2), 152–156 (1997).
   PubMedGoogle Scholar
• Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor α among patients with Kawasaki disease. J. Pediatr.121(6), 924–926 (1992).
   PubMed Web of Science ®Google Scholar
• Maury CP, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor-α in patients with Kawasaki disease. J. Lab. Clin. Med.113(5), 651–654 (1989).
   PubMedGoogle Scholar
• Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler. Thromb. Vasc. Biol.23(4), 576–581 (2003).
   PubMed Web of Science ®Google Scholar
• Yasukawa K, Terai M, Shulman ST et al. Systemic production of vascular endothelial growth factor and FMS-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation105(6), 766–769 (2002).
   PubMed Web of Science ®Google Scholar
• Freeman AF, Crawford SE, Cornwall ML, Garcia FL, Shulman ST, Rowley AH. Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium. Pediatr. Cardiol.26(5), 578–584 (2005).
   PubMedGoogle Scholar
• Miura M, Garcia FL, Crawford SE, Rowley AH. Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr. Infect. Dis. J.23(10), 931–936 (2004).
   PubMedGoogle Scholar
• Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J. Immunol.166(2), 1334–1343 (2001).
   PubMed Web of Science ®Google Scholar
• Rowley AH, Baker SC, Shulman ST et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J. Infect. Dis.190(4), 856–865 (2004).
   PubMedGoogle Scholar
• Rowley AH, Shulman ST, Garcia FL et al. Cloning the arterial IgA antibody response during acute Kawasaki disease. J. Immunol.175(12), 8386–8391 (2005).
   PubMedGoogle Scholar
• Rowley AH, Baker SC, Shulman ST et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J. Infect. Dis.192(10), 1757–1766 (2005).
   PubMedGoogle Scholar
• Rowley AH, Baker SC, Shulman ST et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE3(2), e1582 (2008).
   PubMedGoogle Scholar
• Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics112(3 Pt 1), 495–501 (2003).
   PubMedGoogle Scholar
• Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005–2006. J. Epidemiol.18(4), 167–172 (2008).
   PubMed Web of Science ®Google Scholar
• Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr. Res.65(5 Pt 2), 46R–54R (2009).
   PubMedGoogle Scholar
• Onouchi Y, Tamari M, Takahashi A et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J. Hum. Genet.52(2), 179–190 (2007).
   PubMedGoogle Scholar
• Onouchi Y, Gunji T, Burns JC et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet.40(1), 35–42 (2008).
   PubMed Web of Science ®Google Scholar
• Burgner D, Davila S, Breunis WB et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet.5(1), e1000319 (2009).
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of γ globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med.324(23), 1633–1639 (1991).
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous γ globulin. N. Engl. J. Med.315(6), 341–347 (1986).
   PubMed Web of Science ®Google Scholar
• Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J. Pediatr.140(4), 450–455 (2002).
   PubMedGoogle Scholar
• Muta H, Ishii M, Egami K et al. Early intravenous γ-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J. Pediatr.144(4), 496–499 (2004).
   PubMedGoogle Scholar
• Zhang T, Yanagawa H, Oki I, Nakamura Y. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr.91(5), 517–520 (2002).
   PubMed Web of Science ®Google Scholar
• Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on γ globulin dose but independent of salicylate dose. J. Pediatr.131(6), 888–893 (1997).
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics114(6), 1708–1733 (2004).
   PubMed Web of Science ®Google Scholar
• Jibiki T, Terai M, Kurosaki T et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J. Pediatr.163(4–5), 229–233 (2004).
   PubMedGoogle Scholar
• Inoue Y, Okada Y, Shinohara M et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J. Pediatr.149(3), 336–341 (2006).
   PubMed Web of Science ®Google Scholar
• Newburger JW, Sleeper LA, McCrindle BW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med.356(7), 663–675 (2007).
   PubMed Web of Science ®Google Scholar
• Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr. Infect. Dis. J.23(5), 463–464 (2004).
   PubMedGoogle Scholar
• Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. γ globulin re-treatment in Kawasaki disease. J. Pediatr.123(4), 657–659 (1993).
   PubMed Web of Science ®Google Scholar
• Burns JC, Mason WH, Hauger SB et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr.146(5), 662–667 (2005).
   PubMed Web of Science ®Google Scholar
• Burns JC, Best BM, Mejias A et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr.153(6), 833–838 (2008).
   PubMed Web of Science ®Google Scholar
• Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous γ-globulin treatment failure in Kawasaki disease. Pediatrics105(6), E78 (2000).
   PubMed Web of Science ®Google Scholar
• McMorrow Tuohy AM, Tani LY, Cetta F et al. How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease? Am. J. Cardiol.88(3), 328–330 (2001).
   PubMedGoogle Scholar
• Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics100(4), 695–699 (1997).
   PubMedGoogle Scholar
• Gotteiner N, Mavroudis C, Backer CL et al. Coronary artery bypass grafting for Kawasaki disease. Pediatr. Cardiol.23(1), 62–67 (2002).
   PubMedGoogle Scholar
• Ishii M, Ueno T, Akagi T et al. Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr. Int.43(5), 558–562 (2001).
   PubMed Web of Science ®Google Scholar
• Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics109(1), E4 (2002).
   PubMed Web of Science ®Google Scholar
• Sugimura T, Yokoi H, Sato N et al. Interventional treatment for children with severe coronary artery stenosis with calcification after long-term Kawasaki disease. Circulation96(11), 3928–3933 (1997).
   PubMedGoogle Scholar
• Kitamura S, Tsuda E, Kobayashi J et al. Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation120(1), 60–68 (2009).
   PubMedGoogle Scholar
• Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet2(8154), 1216–1217 (1979).
   PubMed Web of Science ®Google Scholar
• Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet2(8397), 255–256 (1984).
   PubMed Web of Science ®Google Scholar
• Kenyon RH, Condie RM, Jahrling PB, Peters CJ. Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells. Microb. Pathog.9(4), 219–226 (1990).
   PubMedGoogle Scholar